Seattle-based biotech startup Kineta today announced that it won a $ 7.2 million award to develop an antiviral drug therapy for treating Lassa haemorrhagic fever.
The money comes from The Wellcome Trust, a London-based...
Seattle-based biotech startup Kineta today announced that it won a $ 7.2 million award to develop an antiviral drug therapy for treating Lassa haemorrhagic fever.
The money comes from The Wellcome Trust, a London-based...
The Electronic Frontier Foundation's "Stupid Patent of the Month" for December isn't owned by a sketchy shell company, but rather the Microsoft Corporation. The selection, published yesterday, is the first time the EFF has picked a design patent as the SPOTM. The blog post seeks to highlight some of the problems with those lesser-known cousins to standard "utility" patents, especially the damages...